Predictors for Initiation of Atypical Long-Acting Injectable Antipsychotic Agents in a Commercial Claims Cohort of Individuals With Early-Phase Schizophrenia
This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.
This content is restricted to subscribers
Continue Reading...
Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Members enjoy free PDF downloads on all articles. Join today
Author Affiliations
The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York
Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, New York
Corresponding author: Jose M. Rubio, MD, Zucker Hillside Hospital—Ambulatory Care Pavilion, Division of Psychiatry Research, Ste PRA-17, 75-59 263rd St, Glen Oaks, NY 11004 ([email protected]).
Teva Branded Pharmaceutical Products R&D, Inc., Global Health Economics and Outcomes Research, West Chester, Pennsylvania
Teva Branded Pharmaceutical Products R&D, Inc., Global Health Economics and Outcomes Research, West Chester, Pennsylvania
Teva UK Limited, Global Medical Affairs, Harlow, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc., Clinical and Real World Evidence Statistics, West Chester, Pennsylvania
Teva Branded Pharmaceutical Products R&D, Inc., Clinical and Real World Evidence Statistics, West Chester, Pennsylvania
The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York
Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, New York
References (41)
Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1(1):15067. PubMedCrossRef
Patel KR, Cherian J, Gohil K, et al. Schizophrenia: overview and treatment options. P&T. 2014;39(9):638–645. PubMed
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. PubMedCrossRef
Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005;17(3):137–140. PubMedCrossRef
López-Muñoz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17(3):113–135. PubMedCrossRef
Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071. PubMedCrossRef
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. PubMedCrossRef
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226. PubMedCrossRef
Lopez LV, Shaikh A, Merson J, et al. Accuracy of clinician assessments of medication status in the emergency setting: a comparison of clinician assessment of antipsychotic usage and plasma level determination. J Clin Psychopharmacol. 2017;37(3):310–314. PubMedCrossRef
Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404. PubMedCrossRef
Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693. PubMedCrossRef
Taipale H, Mittendorfer-Rutz E, Alexanderson K, et al. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia. Schizophr Res. 2018;197:274–280. PubMedCrossRef
Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(suppl 14):27–30. PubMed
Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? antipsychotic response in first- vs second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036–1042. PubMedCrossRef
Taipale H, Tanskanen A, Correll CU, et al. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study. Lancet Psychiatry. 2022;9(4):271–279. PubMedCrossRef
Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–1224. PubMedCrossRef
Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry. 2015;72(8):822–829. PubMedCrossRef
Lian L, Kim DD, Procyshyn RM, et al. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: a systematic review and meta-analysis. Early Interv Psychiatry. 2022;16(6):589–599. PubMedCrossRef
Pilon D, Joshi K, Tandon N, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence. 2017;11:619–629. PubMedCrossRef
Bareis N, Olfson M, Wall M, et al. Variation in psychotropic medication prescription for adults with schizophrenia in the United States. Psychiatr Serv. 2022;73(5):492–500. PubMed
Robinson DG, Subramaniam A, Fearis PJ, et al. Focused ethnographic examination of barriers to use of long-acting injectable antipsychotics. Psychiatr Serv. 2020;71(4):337–342. PubMedCrossRef
Weiden PJ, Roma RS, Velligan DI, et al. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015;76(6):684–690. PubMedCrossRef
Şahin OŞ, Mursalova Z, Gadimov S, et al. Predictors of long-acting injectable antipsychotic prescription at discharge in patients with schizophrenia and other psychotic disorders. Int Clin Psychopharmacol. 2021;36(5):251–256. PubMedCrossRef
Rubio JM, Taipale H, Tanskanen A, et al. Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr Bull. 2021;47(6):1611–1620. PubMedCrossRef
Gilbert JL, Nelson LA, Kriz CR, et al. Identifying predictors of primary adherence to second generation long-acting injectable antipsychotics following discharge from an acute inpatient psychiatry unit. Psychopharmacol Bull. 2019;49(2):8–16. PubMed
Üçok A, Yağcioğlu EA, Aydin M, et al. Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder. Int Clin Psychopharmacol. 2021;36(2):89–96. PubMedCrossRef
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. PubMedCrossRef
Quan H, Li B, Couris CM, et al. Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. PubMedCrossRef
Wei Y, Yan VKC, Kang W, et al. Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia. JAMA Netw Open. 2022;5(7):e2224163. PubMedCrossRef
Zichlin ML, Mu F, Leo S, et al. The impact of antipsychotic dose reduction on clinical outcomes and health care resource use among medicare patients with schizophrenia. Clin Drug Investig. 2021;41(10):853–863. PubMedCrossRef
West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995–1001. PubMedCrossRef
Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247. PubMedCrossRef
Keepers GA, Fochtmann LJ, Anzia JM, et al; (Systematic Review). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–872. PubMedCrossRef
Pelayo-Terán JM, Gajardo Galán VG, de la Ortiz-García de la Foz V, et al. Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). Eur Arch Psychiatry Clin Neurosci. 2017;267(4):315–323. PubMedCrossRef
Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965. PubMedCrossRef
He H, Liu Q, Li N, et al. Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017. Epidemiol Psychiatr Sci. 2020;29:e91. PubMedCrossRef
Caroli F, Raymondet P, Izard I, et al. Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011;5:165–171. PubMedCrossRef
Heres S, Schmitz FS, Leucht S, et al. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275–282. PubMedCrossRef
Kane JM, Correll CU. Optimizing treatment choices to improve adherence and outcomes in schizophrenia. J Clin Psychiatry. 2019;80(5):IN18031AH1C. PubMedCrossRef